Klotho Neurosciences signs $250K manufacturing deal with AAVnerGene for KLTO-202 gene therapy

Greenland Mines Ltd

Initial fees of $250,000; additional fees tied to clinical trial stages plus 2% royalty on product revenue.
Agreement covers manufacturing and development of KLTO-202 using AAVnerGene's AAVone platform technology.
AAVnerGene's ATHENA tissue-targeting system aims to avoid liver homing and reduce inflammatory side effects.
CEO states partnership expected to lower cost, increase purity, and accelerate time to clinic.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.